SCHEMBL547396

SCHEMBL547396

C=CCc1c[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
HTT P42858 2/20 0.65
LMNA P02545 1/20 0.65
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
CYP3A4 P08684 3/20 0.62
MAPT P10636 3/20 0.62
AHR P35869 1/20 0.62
GPR84 Q9NQS5 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
HTR2A P28223 5/20 0.59
HTR2C P28335 4/20 0.59
HTR6 P50406 4/20 0.59
HTR1A P08908 4/20 0.59
HTR1D P28221 3/20 0.59
HTR2B P41595 3/20 0.59
ADRA2A P08913 2/20 0.59
SLC6A2 P23975 2/20 0.59
HTR1E P28566 2/20 0.59
SLC6A4 P31645 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10382799 0.84 MEN1 (0.67) ALDH1A1HTTLMNAMEN1KMT2A
Quinoline SCHEMBL28296371 0.83 ALDH1A1 (0.48) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL6803427 0.81 MEN1 (0.58) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL28231921 0.81 MEN1 (0.58) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL6157000 0.81 HTR2A (0.65) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL6156912 0.81 MEN1 (0.58) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL29376106 0.81 MEN1 (0.62) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL4656420 0.81 MEN1 (0.62) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2485762 0.81 MEN1 (0.62) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL1327214 0.81 MEN1 (0.62) ALDH1A1HTTMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116924964-A Preparation method of tetrahydrocarbazole ring compound 四川轻化工大学 2023-10-24 CN claimed
CN-114702429-B Method for constructing 3-alkyl indole compounds by olefin difunctional 南昌航空大学 2023-06-02 CN claimed
CN-114702429-A Method for constructing 3-alkyl indole compound by olefin dual-functionalization 南昌航空大学 2022-07-05 CN claimed
CN-114014859-A Triazole indolol compound and synthesis method thereof 绍兴文理学院 2022-02-08 CN claimed
CN-112876401-A Synthesis method of chiral 3-allylindole compound 江苏师范大学 2021-06-01 CN claimed
CN-101245046-B 3-indole-1-propylene compounds, process for synthesizing 3-indole-1-propylene compounds and uses thereof SHANGHAI INST ORGANIC CHEM 2011-04-06 CN claimed
CN-101245046-A Process for synthesizing 3-indole-1-propylene compounds and uses thereof SHANGHAI INST ORGANIC CHEM (CN) 2008-08-20 CN claimed
WO-2003018192-A2 METHOD FOR THE PRODUCTION OF 2-PROPYLHEPTANOL AND HYDROFORMYLATING CATALYSTS AND THE FURTHER USE THEREOF FOR CARBONYLATION, HYDROCYANATION AND HYDROGENATION BASF AKTIENGESELLSCHAFT (DE) 2003-03-06 WO claimed
EP-0758893-A1 POTENTIATED ANTIBIOTIC COMPOSITION Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1997-02-26 EP claimed
WO-1995030417-A1 POTENTIATED ANTIBIOTIC COMPOSITION ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1995-11-16 WO claimed
WO-2024148030-A1 KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF ATOSSA THERAPEUTICS, INC. (US) 2024-07-11 WO disclosed
US-20240131005-A1 COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY BOULDER BIOSCIENCE LLC 2024-04-25 US disclosed
WO-2024073473-A1 COMPOSITIONS COMPRISING 3,3'-DIINDOLYLMETHANE FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY BOULDER BIOSCIENCE LLC (US) 2024-04-04 WO disclosed
CN-117417253-A Method for preparing phenyl alkyl acid ester by alkyl olefin 常州大学 2024-01-19 CN disclosed
CN-117186089-A Preparation method of tetrahydrocarboline derivative 浙江大学 2023-12-08 CN disclosed
WO-1996010014-A1 ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-04-04 WO disclosed
WO-1995030417-A1 POTENTIATED ANTIBIOTIC COMPOSITION ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1995-11-16 WO disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240131005-A1 COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY NOTCH3, C1S, ADAM33 ALDH1A1 3016/4885HTT 967/4885LMNA 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.